Nitazoxanide against COVID-19 in three explorative scenarios

Calderón, José Meneses; Flores, Ma Del Rocío Figueroa; Coria, Leopoldo Paniagua; Garduño, Jesús Carlos Briones; Figueroa, Jazmín Meneses; Contretas, María José Vargas; Ávila, Lilia De la Cruz; Meza, Salvador Díaz; Chacón, Reynaldo Ramírez; Padmanabhan, Srivatsan; Zerón, Hugo Mendieta

doi:10.3855/jidc.13274

Cited by 28 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efficacy of azithromycin is well established in cases of community acquired pneumonia (CAP), but it is effects on viruses lacks evidence (Sultana et al 2020 ). Besides azithromycin, clarithromycin has also been used in COVID-19 patients (Calderón et al 2020 ). WHO has also reported the widespread use of azithromycin especially with hydroxychloroquine even beyond recommendations (WHO 2020 , NICE 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Antibacterial agents used in COVID-19: A systematic review and meta-analysis

Sharma

Singh

Banerjee

2021

Environmental Sustainability

View full text Add to dashboard Cite

There have been speculations regarding rise in antimicrobial resistance (AMR) globally owing to indiscriminate antibiotic usage during the COVID-19 pandemic. To curb the menace through decisive policies, it is essential to assess the antibiotics, particularly the antibacterial agents. This systematic review and meta-analysis were performed to assess antibiotic use in COVID-19 patients. A thorough systematic search was undertaken in databases like PubMed, Cochrane library, Google Scholar, World Health Organization (WHO) database and clinicaltrials.gov by two independent reviewers for articles in English published from January 1, 2019 to October 31, 2020. Studies were included if they assessed confirmed COVID-19 cases and mentioned the use of antibiotics. The primary outcome was the proportion of COVID-19 patients subjected to specific antibacterial agents. An attempt to stratify the data based on study settings and disease severity was also performed. Of the total 6012 studies screened, 40 were eligible for qualitative review and 19 for meta-analysis. Specific antibacterial agents were mentioned in 23 studies (57.5%). In the random effect meta-analysis, pooled prevalence of azithromycin use was 24.5% (95% CI 22.9–26.2%) followed by cephalosporins as 26.6% (95% CI 24.9–28.4). None of the studies clearly specified indications for antibiotic use. Ten studies (25%) mentioned empirical use of antibiotics. Bacterial co-infections/secondary infections were documented in four studies with mean prevalence of infection of 1.9% (95% CI 1.2–2.8%). There is lack of data on use of specific antibacterial agents, indications for their use based on severity of infections and microbiological evidence of bacterial co-infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibacterial agents used in COVID-19: A systematic review and meta-analysis

Sharma

Singh

Banerjee

2021

Environmental Sustainability

View full text Add to dashboard Cite

show abstract

“…46,47 Nitazoxanide is safe to take during pregnancy (Category B), but proper dosing remains uncertain for purposes of PrEP. 48 Tafenoquine is contraindicated in pregnancy due to inadequate human data (no assigned pregnancy category) and potential risk of abortion based on animal studies. 49 A recent British study found that macrolides taken during pregnancy may be associated with an increased risk of birth defects.…”

Section: Other Options For Pregnancy Prepmentioning

confidence: 99%

Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women

Fesler¹,

Stricker²

2021

IJGM

View full text Add to dashboard Cite

Pregnant women are at higher risk for developing severe complications of COVID-19 including preterm delivery, respiratory failure, and death. Although vaccines to prevent COVID-19 are being developed, pregnant women are not included in the current COVID-19 vaccine trials and initially this population may not be eligible for COVID-19 vaccines due to lack of safety testing in pregnancy. As an alternate approach, we discuss the concept of pre-exposure prophylaxis (PrEP) using medications that are approved for use in pregnant women to prevent gestational problems and severe illness in this high-risk population. In particular, the use of hydroxychloroquine PrEP affords a safe and readily available means to avoid COVID-19 complications in pregnancy.

show abstract

“…Nitazoxanide, previously used as an antihelminthic agent, has proved an in vitro broad antiviral activity and is known to have a relatively favourable safety profile [11]. A study published by Calderon M et al on 17 pregnant women reported positive results [52]. Camostat mesylate, used in Japan for the treatment of pancreatitis, also proved an antiviral activity in vitro by preventing the virus entry into the cells, through inhibition of a host serine protease [11].…”

Section: Other Drugsmentioning

confidence: 99%

Study of Available Antiviral Treatments for Covid-19 During Pregnancy

OLARU¹

2020

FARMACIA

View full text Add to dashboard Cite

Since the end of the year 2019, mankind has been confronting with the COVID-19 pandemic. Complex measures have been taken to solve this problem and the aim of this study is to summarise the results of research on the most used antiviral treatments for COVID-19 diagnosed in pregnant women. The specialty literature review was conducted by searching the PubMed (National Library of Medicine, Washington, DC) and Embase (Elsevier) databases. In the initial search in databases we used a combination of the following keywords: "COVID-19", "SARS-CoV-2", "pregnancy" and "therapy". Clinical trials were identified using the search term "COVID-19" and the generic names of the drugs on ClinicalTrials.gov and International Clinical Trials Registry Platform (ICTRP) of WHO. Corresponding to the objectives of our research, we found articles and studies about antiviral drugs which act as: protease inhibitors (lopinavir/ritonavir, darunavir/cobicistat), RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), umifenovir, antimalarial drugs (chloroquine, hydroxyclhoroquine) and others. Summarising what is currently known about the antiviral treatment of COVID-19 during pregnancy, we can conclude that, at this time, no antiviral drug is undoubtedly effective in the fight against SARS-CoV-2; the experience gained so far, leads to the idea that treatment schemes must combine several methods and drugs to be successful; a national or even international register should be set up to report situations where a medicine has been administered to a pregnant woman to monitor for side effects; pregnant women should also be included in studies, under rigorous conditions and after a clear demonstration of the effectiveness of medicines. Rezumat De la sfârșitul anului 2019, omenirea se confruntă cu pandemia COVID-19. Au fost luate măsuri complexe pentru a rezolva această problemă, iar scopul acestui studiu este de a face o sinteză a rezultatelor cercetărilor privind cele mai utilizate tratamente antivirale pentru COVID-19, la femeile gravide. Revizuirea literaturii a fost efectuată prin căutarea în bazele de date PubMed (Biblioteca Națională de Medicină, Washington, DC) și Embase (Elsevier). În căutarea inițială din bazele de date a fost folosită o combinație a următoarelor cuvinte cheie: "COVID-19", "SARS-CoV-2", "sarcină" și "terapie". Studiile clinice au fost identificate folosind termenul de căutare "COVID-19" și denumirile generice ale medicamentelor de pe ClinicalTrials.gov și Platforma internațională de înregistrare a studiilor clinice (ICTRP) a Organizației Mondiale a Sănătății (OMS). Corespunzând obiectivelor cercetării desfășurate, au fost găsite articole și studii despre medicamente antivirale care acționează ca: inhibitori de protează (lopinavir/ritonavir, darunavir/cobicistat), inhibitori de ARN polimerază (remdesivir, favipiravir, ribavirin), umifenovir, medicamente antimalarice (clorochină, hidroxiclorochină) și altele. Rezumând ceea ce se știe în prezent despre tratamentul antiviral al COVID-19 în timpul sarcinii, putem concluzi...

show abstract

Nitazoxanide against COVID-19 in three explorative scenarios

Cited by 28 publications

References 21 publications

Antibacterial agents used in COVID-19: A systematic review and meta-analysis

Antibacterial agents used in COVID-19: A systematic review and meta-analysis

Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women

Study of Available Antiviral Treatments for Covid-19 During Pregnancy

Contact Info

Product

Resources

About